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Abstract
Background: The average incidence of preterm birth in the world is up to 11.1 %, and deaths of preterm children
account for more than 50 % of neonatal deaths. Gastrointestinal function of preterm children with a gestational age
less than 34 weeks is immaturely developed. For preterm children who can only be fed with formula due to their
mothers’ sickness, choosing a suitable formula can not only meet the high nutritional needs of preterm children,
but also solve their low gastrointestinal tolerability, and is thus very important.
Methods/Design: The study is a prospective, randomized, single-blind and controlled clinical trial. Preterm children
with a gestational age less than 34 weeks meeting the inclusion criteria who cannot be breastfed will be included.
To demonstrate the application effect of extensively hydrolyzed milk protein formula on the target population,
preterm children will be randomized into two groups, 185 subjects in each group. The observation group will be
fed with extensively hydrolyzed milk protein (100 % whey protein) formula, while the control group will be fed with
preterm children’s formula until the children are discharged from the neonatal intensive care unit (NICU). All the
formula involved in this study will be from Dumex. After discharge, both groups will be uniformly fed with formula
for 0 to 6-month-old infants. For statistical analysis, a chi-square test and Student’s t test will be applied using SAS 9.4.
Discussion: This will be the first randomized controlled clinical study with long-term observation of the growth and
development of preterm children during the NICU stay and at 3-month follow-up after discharge from the NICU.
Results from this study will be used to determine whether the extensively hydrolyzed formula is more suitable for the
low gastrointestinal tolerability of preterm children, and also whether feeding preterm children who are fed with such
formula during the NICU stay with ordinary infant formula after discharge from the NICU would affect the normal
growth and development of preterm children in the early stage of their lives.
Trial registration: This study was registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn/) with
number ChiCTR-IOR-14005696, on December 22, 2014.
Keywords: Extensively hydrolyzed formula, Preterm children, Feeding intolerance, Growth and development, Follow-up
* Correspondence: qiao_lixing@163.com
†Equal contributors
Department of Paediatrics, Zhongda Hospital Southeast University,
87 Dingjiaqiao, Nanjing 210009, China
TRIALS
© 2015 Yin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yin et al. Trials  (2015) 16:498 
DOI 10.1186/s13063-015-1030-5
Background
The neonatal period is a special period of life, in which
the infant gradually transforms from complete depend-
ence on the mother for survival into a mature individual.
In 1976, the World Health Organization (WHO) defined
preterm children as newborns with a gestational age of
<37 weeks (<259 days) [1]. In 2005, the American Acad-
emy of Pediatrics and the American College of Obstetri-
cians and Gynecologists [2] defined newborns with a
gestational age of 34–36+6 weeks as late preterm birth,
and less than 34 weeks as early preterm birth; in 2012,
the WHO [3] defined preterm children with a gesta-
tional age of <28 weeks as extremely preterm birth,
28–31+6 weeks as very preterm birth, 32–36+6 weeks as
moderate preterm birth, and 34–36+6 weeks as late pre-
term birth. The incidence of preterm birth varies greatly
in different countries. In 2010, the incidence of preterm
birth in 11 countries worldwide was ≥15 % [4]. The aver-
age incidence of preterm birth all over the world is up to
11.1 %. A total of 14.9 million preterm children are born
worldwide every year [5], and in these preterm live births,
more than 1 million preterm children eventually die [6],
accounting for more than 50 % of neonatal deaths. In
China, there is little data on the incidence of preterm birth
nationwide. The WHO reported that the incidence of pre-
term birth in China in 2010 was <10 % [4]. The num-
ber of preterm children in ten countries including China
accounts for 60 % of the world’s total. The mortality of
preterm children in China is very high. From 2000 to
2008, preterm children led to 14–15 % of deaths of chil-
dren younger than 5 years old in China [7]. The younger
the gestational age, the lower the birth weight is and the
higher the mortality is. According to the above data, we
find that in all medical problems of newborns, the im-
provement of the survival rate and quality of life of pre-
term children is the target that the world focuses on
tackling.
The fetus in utero obtains nutrition through the pla-
centa as a parenteral nutrition (PN) pathway. After birth,
the newborns need to switch to enteral nutrition, while
the completion of enteral nutrition requires effective and
coordinated sucking-swallowing, gastric emptying, intes-
tinal peristalsis and the digestion and absorption of nu-
trients. However, these functions of preterm children are
immature, and the younger the gestational age, the more
immature these functions. First, the increase in the
extensibility and absorption area (microvilli) of the gastro-
intestinal tract of preterm children is mainly completed in
the last 3 months of pregnancy [8]. Second, the sucking-
swallowing-breathing action of preterm children with a
gestational age of less than 32 weeks is much more unco-
ordinated; only children with a gestational age of 34–35
weeks have coordinated nutritive sucking [9]. In addition,
the gastrointestinal motility of preterm children is weak,
and the duodenum of preterm children with a gestational
age of <32 weeks lacks the spread of migrating motor
complex (MMC) [10]. Until after the gestational age of
34 weeks, clear and ever-increasing MMC gradually
emerge. The above mechanisms lead to prolonged gastric
emptying time and intestinal transit time of food in
preterm children, and thus preterm children with a
gestational age of less than 34 weeks are prone to gastro-
esophageal reflux, feeding intolerance (FI), delayed meco-
nium drainage, intestinal dilatation and other phenomena.
In addition, the development of digestive enzymes in pre-
term children is also very immature, and preterm children
have inadequate secretion and low activity of gastric acid,
gastric protease-pepsin and pancreatic protease, which
weaken the ability of the gastrointestinal tract to hydrolyze
protein into peptides and amino acids [10]; the concentra-
tion of pancreatic lipases and duodenal bile acids is very
low [11], which reduces the intestinal absorption of lipids,
especially the long-chain fatty acids (LCT). Therefore, pre-
term children are also prone to extrauterine growth re-
tardation (EUGR) caused by inadequate absorption of
enteral nutrition. Currently, a large number of studies
have shown that extrauterine growth retardation has def-
inite influences on the subsequent cognition and mental
development of preterm children [12].
Nutritional support in the neonatal period is one of
the basic conditions for survival of preterm children.
Preterm children born in advance for various reasons
need parenteml nutrition if enteral nutrition cannot
meet their needs for growth and development. Although
parenteral nutrition supplement can meet the temporary
nutritional needs of preterm children, long-term paren-
teral nutrition has brought a series of problems, such
as difficulties in peripheral venous puncture, suscepti-
bility to complication by infections after central venous
catheterization, parenteral nutrition-associated cholestasis
(PNAC) and other complications. The ultimate goal of nu-
tritional support in preterm children is to not only reach
the normal growth speed of normal fetuses of similar ges-
tational age in utero, but also have similar composition
and function to normal fetuses. The ideal growth rate of
preterm/low-birth-weight children during the neonatal in-
tensive care unit (NICU) stay, by referring to the growth
rate of normal fetuses in utero [13], is required as follows:
average daily weight gain of 15 g/kg, weekly body length
growth of 1 cm and weekly head circumference growth of
0.5–1 cm. However, preterm children after birth are faced
with respiratory, digestive and other problems. For pre-
term children with various immaturely developed systems,
how to solve the conflict between the high nutritional de-
mands and low gastrointestinal tolerability of preterm
children is a very realistic and important issue. Therefore,
we need an appropriate early enteral nutrition manage-
ment strategy for preterm children, although there is
Yin et al. Trials  (2015) 16:498 Page 2 of 15
already a lot of consensus [14, 15], such as breastfeeding,
initiation of microfeeding as early as possible, achieving
full enteral nutrition as soon as possible, and shortening
the time of parenteral nutrition in order to reduce compli-
cations. It is preferred to feed preterm children with their
mothers’ breast milk [14], because such feeding can re-
duce the incidence of feeding intolerance, neonatal necro-
tizing enterocolitis (NEC), nosocomial infections, and
growth and developmental retardation in preterm children
[16]. In the event of inadequate supply of breast milk due
to various reasons or inability of breastfeeding due to
maternal diseases, breast milk provided by qualified
breast milk donors becomes the second-best nutri-
tional source for preterm children [17] During October
2010 to December 212, a multicenter double-blind con-
trolled study conducted in Canada [18] found that the
breast milk of donors was equally safe and effective as the
breast milk of preterm children’s mothers, and after long-
term follow-up and study, found that donor breastfeeding
was favorable for the development of the nervous system
in preterm children. In Taiwan, China [19], the breast milk
in the breast milk bank is mainly used for feeding preterm
children, infants with feeding intolerance and other infants
suffering from metabolic disorders. Currently, many de-
veloped countries have established large breast milk
banks, and breast milk can be shared even via the Internet
[20]. However, the breast milk in breast milk banks is
mostly for full-term children, whose nutritional ingredi-
ents cannot meet the needs of growth and development of
preterm children. Breast milk banks have not been set up
in most areas of China, and no unified standard donor
screening, breast milk collection, disinfection, preserva-
tion and feeding practices have been established. The rural
population accounts for the majority in China. Rural areas
and small cities lack the capacity to treat preterm children,
so preterm children are often sent to NICU in large cities
for hospitalization. Their homes are often far away from
the hospital, and China’s NICUs are mostly accompany-
free wards, so family members cannot participate in feed-
ing and care. Besides, many mothers cannot breastfeed
because of their illness, and thus, preterm children hospi-
talized in NICUs in China are mostly fed with formula.
In China, preterm children with a gestational age of
less than 34 weeks are mostly fed with preterm chil-
dren’s formula, and such milk powder provides sufficient
energy, protein, vitamins and minerals and features a
high growth rate in preterm children. However, excessive
weight gain in early infancy will increase the risk of
metabolic diseases and cardiovascular diseases in adult-
hood [21, 22]. The probabilities of feeding intolerance
and neonatal necrotizing enterocolitis and overall mor-
tality in preterm children fed with preterm children’s
formula are significantly higher than in children fed with
breast milk or donated breast milk [23–25]. Therefore,
choosing a milk powder more suitable for the intestinal
function of preterm children with a gestational age of
less than 34 weeks is very important.
Hydrolyzed formula is to hydrolyze protein in milk
powder to polypeptides, peptides and free amino acids
with bio-lyase, heating, ultrafiltration and other special
technologies. The American Academy of Pediatrics (AAP)
refers to formula whose peptide molecular weight is less
than 3000 Da as extensively hydrolyzed formula (EHF)
[26]. According to the protein ingredient therein, the for-
mula can be divided into hydrolyzed protein formula, hy-
drolyzed soy protein formula and hydrolyzed rice protein
formula; according to the milk protein ingredient therein,
the formula can be divided into hydrolyzed whey protein,
hydrolyzed casein, and hydrolyzed whey protein/casein.
The low-molecular-weight peptides and small amounts of
free amino acids in extensively hydrolyzed milk protein
formula have greatly reduced the conformation and se-
quence of allergen idiotope, and thus the antigenicity is
greatly lowered. The milk powder is mainly used for the
treatment of cow’s milk protein allergy (CMPA) [27].
Researchers have fed preterm children in their early
stage of life with EHF to prevent the occurrence of CMPA
[28, 29], but there is no conclusion on whether it is
effective.
EHF has cracked milk protein to low-molecular-
weight peptides and partial amino acids, favorable for
the gastrointestinal tolerability of preterm children.
Frati et al. [30] and Staelens et al. [31] found by adopt-
ing different methods that the gastric emptying of EHF
was significantly faster than the ordinary formula
group; Mihatsch et al. [32] used carmine as a fecal
marker and found that in preterm children, the gastro-
intestinal transit time of extensively hydrolyzed formula
was 9.8 hours, while that of standard ordinary formula
was 19 hours. The main mechanisms that EHF is fa-
vorable for the gastrointestinal tolerability of preterm
children are summarized as follows: (1) it promotes
gastric emptying [30, 31, 33, 34]; (2) it accelerates
gastrointestinal transit [32]; (3) it reduces the activity
of opioid receptor agonist-milk protein [35]; and (4) it
induces motilin (MOT) and gastrin (GAS) secretion
[36], thereby reducing the incidence of gastroesopha-
geal reflux (GER) [30, 34, 37], feeding intolerance, etc.,
in preterm children [38] so as to achieve full enteral
nutrition as soon as possible and reduce the time of
parenteral intravenous nutrition and a series of compli-
cations caused by parenteral nutrition.
Each 100 ml of the EHF used in this study can provide
66 kcal, whose protein-to-energy ratio (P/E) is 2.42 g/
100 kcal, lower than the P/E recommended by the
European Society for Paediatric Gastroenterology, Hepa-
tology, and Nutrition (ESPGHAN) [39]. Can exten-
sively hydrolyzed milk protein formula meet the high
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nutritional needs of preterm children? Current study
findings have differing conclusions [40–44]. Some stud-
ies conclude, by detecting the concentrations of amino
acids in serum and urine and intestinal absorption of ni-
trogen after preterm children are fed with different milk
powders, that the protein content in hydrolyzed milk
protein formula should be higher than ordinary preterm
children’s formula in order to meet the needs of preterm
children for growth and development [40–42]. However,
these studies all have too small sample size (15 cases, 21
cases, 16 cases), the period of literature [40] study is too
short (the conclusion is drawn from determination of
plasma amino acid concentrations only after cross feed-
ing with the two kinds of milk powder for 5 days), and
in the above studies, the preterm children began to be
fed with hydrolyzed formula after achieving full enteral
feeding (EF) or 1 week after birth instead of feeding
with hydrolyzed formula immediately after birth. Sza-
jewska et al. [43] conducted a randomized controlled
study of up to 12 weeks. The authors randomized low-
birth-weight children for feeding with different milk
powders, then tracked and monitored the growth and
development (weight, body length and head circumfer-
ence growths) and all plasma parameter indicators (urea,
albumin (ALB), prealbumin, transferrin, and concentra-
tion of each amino acid) of these infants at the begin-
ning of feeding, 4 weeks, 8 weeks and 12 weeks after
feeding, and found that the nutrition of extensively hy-
drolyzed whey protein formula was equivalent to that of
the standard preterm children’s formula. In China [44],
a multicenter (eight domestic first-class grade 3 hospi-
tals) controlled clinical study from February 2012 to
December 2013 found that extensively hydrolyzed milk
protein formula could promote the gastrointestinal motil-
ity of preterm children and accelerate their metabolism
and excretion of bilirubin, without increasing the occur-
rence of EUGR at discharge. Besides, there is no study at
home and abroad on whether feeding preterm children
with relatively low-energy low-protein extensively hydro-
lyzed milk protein formula in the early stage of life will
affect their subsequent growth and development. Al-
though studies [28, 29] respectively followed up preterm
children and extremely low-birth-weight children after
feeding with EHF for the early stage of life for 12 months
and 5–7 years, these two studies were conducted only to
observe whether EHF could prevent the subsequent
occurrence of CMPA in preterm children, without
tracking and observing the growth and development
of those preterm children.
The protein in the extensively hydrolyzed milk protein
formula used in this study is 1 % whey protein, without
containing casein. A study has found that the higher the
casein content, the slower the gastric emptying [45].
Each 10 ml of the EHF we use provides 66 kcal with
osmolality of 250 mOsmol/L, lower than traditional
preterm children’s formula. Another study has also
found that the higher the calories provided by each
100 ml of formula, the slower the gastric emptying
[46]. Therefore, in this study, the gastric emptying time
and gastrointestinal transit time in preterm children
fed with extensively hydrolyzed milk protein formula
will be accelerated, thereby reducing the incidence of
feeding intolerance in the preterm children, achieving
full enteral feeding as soon as possible, shortening the
time of parenteral nutrition, and reducing the oc-
currence of complications associated with parenteral
nutrition. This formula has cracked milk protein to
low-molecular-weight peptides and partial amino acids,
it reduces the intestinal load of protein digestion in
preterm children, and is thus favorable for the gas-
trointestinal capacity of preterm children for protein
digestion and absorption. Moreover, medium-chain tri-
glycerides fat (MCT) in the formula accounts for 40 %
of total fat, which is favorable for preterm children’s fat
absorption and utilization. The energy and protein pro-
vided by each 100 ml of the milk powder are lower
than traditional preterm children’s formula, but it may
not affect the early nutrition of preterm children due
to the abovementioned features. Can feeding preterm
children with a gestational age of less than 34 weeks
during the NICU stay with extensively hydrolyzed milk
protein formula meet the preterm children’s needs for
early normal growth and development during hospital
stay and after discharge? In addition to observation of
the preterm children’s growth and development during
the NICU stay, our study will also track and follow up
these preterm children for at least 3 months after they
are discharged from the NICU.
Methods/Design
A prospective, randomized, single-center, single-blind
and controlled clinical trial will be conducted in preterm
children with a gestational age of less than 34 weeks
meeting the inclusion criteria who cannot be breastfed.
The implementer of the study will be the NICU of
Zhongda Hospital Southeast University. The majority of
the center’s preterm children are transferred from other
hospitals in Nanjing or nearby towns, wherein most pre-
term children who cannot be breastfed because their
mothers suffer from infectious diseases or other severe
diseases requiring long-term medication are also trans-
ferred to our hospital. Most preterm children hospital-
ized in our hospital’s NICU can only be fed with
formula. Every year, about 2,000 newborns are hospital-
ized in our hospital’s NICU, and preterm children with a
gestational age of less than 34 weeks account for 10–
15 % of the inpatients, of whom about two thirds can
only be fed with formula.
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Objectives
Primary objective
To determine whether feeding preterm children with a
gestational age of less than 34 weeks during the NICU
stay with extensively hydrolyzed milk protein formula
can reduce the rate of food intolerance or not.
Secondary objective
To test if the feeding preterm children with a gestational
age of less than 34 weeks during the NICU stay with ex-
tensively hydrolyzed milk protein formula can accelerate
the time to achieve full enteral feeding, shorten the time
of parenteral nutrition and NICU stay, benefit spontan-
eous fecal discharge, reduce the occurrence of other
complications associated with parenteral nutrition,
and meet the nutritional needs of preterm children
during the NICU stay, without affecting the early
growth and development of these preterm children during
hospitalization and after discharge.
Study population
Recruitment of participants
Preterm children hospitalized in the NICU of Zhongda
Hospital Southeast University in line with the inclusion
criteria are recruited as participants (Fig. 1).
Inclusion criteria:
1. Gestational age <34 weeks
2. Children who can only be fed with formula due to
their mothers’ sickness
3. Children who are transferred to our hospital’s NICU
immediately after birth, and have not started any
enteral feeding before and during transfer, including
water, glucose, formula, drugs, etc.
4. Children whose cardiovascular, blood and nervous
systems are stable when transferred to the NICU
Exclusion criteria:
1. Occurrence of vomiting, abdominal distension,
gastrointestinal hemorrhage or necrotizing enterocolitis
(NEC) before preparation for enteral feeding
2. Occurrence of cardiovascular, blood and nervous
system instability (such as shock, disseminated
intravascular coagulation (DIS), frequent
convulsions, coma) before preparation for enteral
feeding
3. Discovery of gastrointestinal malformations
(esophageal atresia, esophageal fistula, biliary atresia,
Hirschsprung’s disease, anal atresia, omphalocele,
gastroschisis, congenital malrotation, etc.) before
preparation for enteral feeding or after feeding
4. Children with congenital metabolic diseases and
chromosomal disorders
Fig. 1 CONSORT flowchart of subject enrollment
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5. Children with other serious congenital disorders
(diaphragmatic hernia, cyanotic congenital heart
disease, moderate to severe Pierre-Robin syndrome,
etc.)
6. Renal failure due to various causes
7. Children whose head computed tomography (CT)
or B-mode head ultrasound prompts serious
intracranial hemorrhage or hydrocephalus
8. Use of drugs affecting gastric motility and gastric
acid secretion (H2 receptor antagonists, proton
pump inhibitors, gastrointestinal drugs)
9. Occurrence of stage III necrotizing enterocolitis
during hospital stay requiring transfer to a
Children’s Hospital for observation and surgical
treatment
10. Replacement for formula during hospital stay
11. Death during hospital stay
12. Early discharge against the criteria for discharge
from the NICU
13. Children who suffer from diseases requiring
parenteral nutrition or serious illness requiring
intensive care unit (ICU) hospitalization or
requiring hospitalization and surgery
Criteria for discharge from the NICU or transfer to
direct rooming-in (DRI):
1. Corrected gestational age ≥34 weeks, and weight
≥1500 g
2. No need for oxygen inhalation, stable vital signs, no
apnea phenomenon
3. Able to suck formula on their own, and coordinated
sucking-swallowing-breathing action
4. Having achieved full enteral feeding, daily milk volume
≥150 ml/kg, no need for any intravenous medication
5. Able to maintain normal body temperature at room
temperature of 22–24 °C
6. Each system is free from life-threatening pathological
conditions
7. Birth weight has been restored, and weight begins to
grow steadily
Randomization and blinding
Randomization will be conducted by a researcher not in-
volved in the recruitment and treatment of the partici-
pants. Concealed allocation will be performed using a
set of random numbers placed in sealed opaque enve-
lopes. The participants who meet the eligibility criteria
will be divided into two groups by the physicians on
duty via opening the envelopes. Reference to similar
study literature is made for randomization [28, 31]. As
extensively hydrolyzed milk protein formula and preterm
children’s formula are greatly different in color and
smell, physicians and nurses can easily distinguish these
two formulae. Therefore, the study has chosen single-
blinding, which means that only the participants and
their guardians are unaware of the milk type.
Ethical aspects and informed consent
The study has passed the review of the Clinical Study
Ethics Committee of Zhongda Hospital Southeast Uni-
versity, and the Ethics Committee’s approval number is
2014ZDSYLL115.0. Only the preterm children whose
guardians give informed written consent will be included
in this trial.
Study time
The study started in November 2014 and is expected to
end in November 2017.
Interventions
The observation group is fed with extensively hydrolyzed
milk protein (100 % whey protein) formula, while the
control group is fed with preterm children’s formula
until discharge from the NICU. After discharge, both
groups are uniformly fed with ordinary formula (formula
for 0 to 6-month-old infants).
Study design and outcomes
Outcomes
The first endpoint variable is the rate of food intolerance
in preterm children. The second endpoint variables in-
clude (1) time to achieve full enteral nutrition; (2) time
of parenteral nutrition; (3) time of NICU stay; (4) meco-
nium drainage time; (5) daily spontaneous fecal discharge
conditions; (6) growth and development conditions during
the NICU stay and within 3 months after discharge, in-
cluding daily weight growth rate, weekly body length
growth rate and weekly head circumference growth rate;
(7) different plasma parameter indicators before discharge
from the NICU (total protein (TP), albumin, calcium (Ca),
phosphorus (P), and alkaline phosphatase (ALP)). Other
endpoint variables include the incidences of neonatal nec-
rotizing enterocolitis, cholestasis, parenteral nutrition-
associated cholestasis and congenital hypothyroidism (CH).
Study design
The study includes two stages. In stage I, the study ob-
serves the incidence of feeding intolerance, parenteral
nutrition conditions, spontaneous fecal discharge condi-
tions, growth and development conditions and the inci-
dence of other preterm children’s complications in the
preterm children in the two groups during the NICU
stay. In this stage, different feeding methods and paren-
teral nutrition are regulated according to the gestational
age, birth weight and days after birth of the preterm
children, and unified diagnostic criteria and treatment
methods for different complications are developed. In
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stage II, the study follows up the growth and development
conditions of the preterm children in the two groups on a
regular basis after discharge from the NICU.
Introduction to the formulae
The two kinds of formula for feeding during the NICU stay
and the formula for feeding after discharge from the NICU
are all Dumex, a brand of French Danone-Nutricia for early
life nutrition. In this study, the gestational age of all preterm
children when discharged from the NICU is all ≥34 weeks,
and thus formula suitable for 0 to 6-month-old infants is
uniformly chosen for them after discharge. The ingredients
of such formulae are shown in Table 1.
Stage I: NICU stay
1. Feeding time
 Preterm children without obvious high-risk
factors are fed within 24 hours after birth.
 The feeding of preterm children with birth
weight <1000 g, obvious history of asphyxia at
birth (Apgar score ≤5), severe infection (sepsis,
purulent meningitis, etc.), severe pneumonia or
neonatal respiratory distress syndrome (NRDS)
requiring intubation and mechanical ventilation
should be postponed to 24–72 h after birth
according to the situation.
 During the period when full enteral nutrition is
not achieved, partial parenteral nutrition is given
according to the daily amount of fluid and energy
required by the children; when the children
experience feeding intolerance and necrotizing
enterocolitis and need to be fasting, complete
parenteral nutrition is given; after the conditions
are stable, the children gradually switch to enteral
nutrition and are fed until discharge or transfer
into DRI.
 Children in the two groups are fed with ordinary
formula after discharge or transfer to DRI.
2. Feeding methods
 For preterm children with a gestational age of
<32 weeks, since their sucking-swallowing action
is uncoordinated and respiratory function is not
maturely developed, the children are given tube
feeding (nasogastric tube or orogastric tube)
using the intermittent infusion feeding method.
Every time before feeding, the stomach contents
are drawn to learn about gastric residual volume
(GRV) and nature.
 Children suspected of suffering from
gastroesophageal reflux or delayed gastric emptying
are fed by adopting intermittent/continuous
infusion feeding method with an infusion pump.
 Preterm children with a gestational age of 32–34
weeks are given direct bottle feeding.
 Children with weak sucking ability yet normal
gastric emptying are given bottle feeding first,
and then the remaining milk is given by tube
feeding.
 Children with nasal continuous positive airway
pressure (nCPAP) or intubation and mechanical
ventilation are given tube feeding;
 During tube feeding or fasting period, the
children are given non-nutritive sucking (NNS).
3. Feeding milk volume
 Initial feeding milk volume: according to birth
weight, the children are fed from different initial
milk volume once every two hours, as shown in
Table 2.
 The milk volume begins to increase in the
absence of feeding intolerance in 24-h
observation, and the rates for milk increasing are
shown in Table 2.
4. Fluid amount control [14, 47]
Fluid amount includes the total amount of enteral
nutrition, parenteral nutrition and all other intra-
venous and oral medications. If birth weight is
<1500 g, the fluid amount in the first 24 hours after
birth is 80–100 ml/(kg/d); if birth weight is ≥1500 g,
the fluid amount in the first 24 hours after birth is
60–100 ml/(kg/d); then the amount is incremented at
a rate of 15–20 ml/(kg/d) to reach 150 ml/(kg/d) by
the end of the first week; daily fluid amount is
increased or decreased by 10–20 ml/kg on the basis
of the fluid amount that day according to different
clinical conditions (light therapy, incubator, ventilator,
heart and lung function, urine amount, systemic
edema conditions, biochemical monitoring indicators,
etc.), usually no more than 180 ml/(kg/d).
5. Calorie control [14, 47]
Calorie includes the total calories provided by enteral
feeding and parenteral nutrition. The calorie on the first
day is 40 kcal/kg and then incremented at a rate of
10 kcal/(kg/d). Parenteral nutrition is stopped when en-
teral nutrition reaches 80–100 kcal/(kg/d), and enteral
nutrition 100–120 kcal/(kg/d) is the criterion to achieve
full enteral nutrition.
6. Parenteral nutrition (PN) [14, 47]
 Vessel selection: peripheral vein or central vein,
central vein includes peripherally inserted central
catheter (PICC) and umbilical venous catheter
(PVC).
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Table 1 Table of ingredients of the three formulae




Formula for 0 to 6-month-old
infants (/100 ml)
Energy (kcal/KJ) 80/336 66/278 67/282
Osmolality (mOsmol/L) 360 250 -
Fat (g) 3.8 3.5 3.5
α-linolenic acid (mg) 44 58 42
Linoleic acid (g) 0.6 0.41 0.42
Oleic acid (g) 1.3 1.2 -
Medium-chain triglyceride content (%) 30 % 40 % -
Protein (g) 2.6 (60 % whey protein and 40 % casein) 1.6 (100 % whey protein) 1.4
Carbohydrates 8.4 6.9 7.1




Arachidonic acid (mg) 19 6.6 12
Docosahexaenoic acid (mg) 15 6.6 12
Taurine (mg) 5.5 5.3 5.4
L-carnitine (mg) 1.8 1 1.5
Nucleotides (mg) 3.4 3.2 3.0
Vitamin A (μg) 359 52 65
Vitamin D (μg) 3 1.3 0.95
Vitamin E (mg) 3.5 1 1.2
Vitamin K1 (μg) 6 4.7 5.4
Vitamin B1 (μg) 139 50 58
Vitamin B2 (μg) 199 99 103
Vitamin B6 (μg) 119 40 48
Vitamin B12 (μg) 0.24 0.18 0.31
Nicotinamide acid (μg) 2352 432 517
Folic acid (μg) 35 9 11
Pantothenic acid (μg) 876 327 354
Vitamin C (mg) 17 9 9.2
Biotin (μg) 3.5 2.2 2.3
Choline (mg) 17 10 16
Inositol (mg) 24 3.2 3.8
Sodium (mg) 70 20 20
Potassium (mg) 80 75 69
Copper (μg) 80 40 48
Magnesium (mg) 8 5.1 5.7
Iron (mg) 1.6 0.53 0.71
Zinc (mg) 1.1 0.5 0.5
Manganese (μg) 10 7.4 7.5
Calcium (mg) 100 47 52
Phosphorus (mg) 56 26 31
Iodine (μg) 25 12 11
Chlorine (mg) 85 41 48
Selenium (μg) 4.5 1.5 2.2
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 Method: all children adopt “all in one” parenteral
nutrition. The nutrient solution used for daily
parenteral nutrition is uniformly prepared inside
on a clean bench at the hospital’s Intravenous
Nutrition Preparation Center according to the
doctor’s instructions that day, and attention
should be paid to the sequence of mixing during
preparation. After preparation the solution is
evenly infused via the infusion pump within
24 hours. The total amount of parenteral
nutrition fluid and compounding ratio of all
nutrients are calculated according to the child’s
total fluid amount required that day, total calorie,
milk intake the day before and possible total milk
intake that day.
 Children’s compound amino acid (6 %) 1.0–1.5 g/
(kg/d) is added within 24 hours after birth, which
is later incremented up to 3.5–4.0 g/(kg/d) at a
rate of 0.5 g/(kg/d); medium and long-chain fat
emulsion 0.5 g/(kg/d) is added within 24 hours
after birth, which is later incremented up to
3.0 g/(kg/d) at a rate of 0.5 g/(kg/d).
 Carbohydrates ≤15 g/(kg/d), providing 40–50 %
of the total energy; amino acids ≤3.5–4.0 g/(kg/
d), providing 15–20 % of the total energy, fat
emulsion ≤3.0 g/(kg/d), providing 40–50 % of the
total energy.
 Sodium ions 2.0–3.0 mmol/L and potassium ions
1.0–2.0 mmol/L are supplemented daily, but
within 3 days after birth, no potassium is
supplemented in principle unless the child is
suffering from hypokalemia.
 A variety of water-soluble and fat-soluble
vitamins 0.5–1.0 ml/(kg/d) are supplemented.
 If the child has cholestasis, the amount of
intravenous fat emulsion is reduced.
 The concentration and rate of intravenous
nutritive sugar are adjusted according to the
child’s blood glucose monitoring. In case of
PVC or PICC, the sugar concentration is
≤15 %; when peripheral intravenous infusion
is adopted, the sugar concentration is ≤12.5 %.
The child’s blood glucose is controlled at
3.0–7.0 mmol/L.
7. Diagnostic criteria for and treatment of various
complications:
1. Diagnostic criteria for and clinical treatment of
feeding intolerance [48, 49]
Children in line with any of the following six criteria
can be diagnosed with feeding intolerance:
 Gastric residual liquid >50 % of the amount of
previous feeding
 Vomiting ≥3 times/day, or the vomitus is bile-like
 Gastric residual liquid or vomitus is bile-like or
coffee grounds-like
 Abdominal distension (abdominal girth is increased
by ≥1.5 cm within 24 hours, with intestinal type),
and abdominal distension caused by the use of
nCPAP should be ruled out
 Required fasting >2 meals
 Blood in the stool or fecal occult blood positive, but
it is required to rule out NEC based on the general
conditions, blood indicators and abdominal X-ray
examination of children
Clinical treatments:
 Amount of gastric residue: for children with tube
feeding, draw the residual milk in the stomach every
time before feeding.
(a) If birth weight is <1500 g, and gastric residue is
<2 ml or if birth weight is ≥1500 g and gastric
residue is <3 ml or gastric residue is <30 % of the
amount of previous feeding, continue feeding and
closely observe.
(b)If gastric residue is 30–50 % of the amount of
previous feed, reduce the amount of feeding.
(c) If gastric residue is >50 % of the amount of
previous feeding, fast for one meal, and continue
feeding by the original feeding plan after the
condition is improved.
(d)If there is bile-like or coffee grounds-like liquid
in the gastric residual liquid or vomitus, stop
feeding.
 Abdominal distension: measure the abdominal
girth at fixed parts every time before feeding. If
the abdominal girth is increased by ≥1.5 cm,
reduce the amount of feeding or fast for one
meal, and continue feeding by the original feeding
plan after the abdominal distension condition is
improved.
 If daily vomiting occurs >3 times, do not
increase the milk volume or reduce the amount
of feeding.
 In the event of blood in the stool or fecal occult
blood positive, stop feeding.
Table 2 Initial feeding milk volume and increasing rate in the
two groups of preterm children
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2. Diagnostic and treatment reference criteria for
necrotizing enterocolitis (NEC) [50] are shown in
Table 3.
3. Diagnostic criteria for and clinical treatment of
cholestasis:
Diagnostic criteria [51]: in line with any of the first
two criteria:
 Total bilirubin (TB) <5 mg/dl and direct bilirubin
(DB) >1.0 mg/dl
 TB >5 mg/dl and DB >20 % of TB
 Elevated total bile acid (TBA) levels alone cannot
serve as a diagnostic criterion for cholestasis
4. Diagnosis and clinical treatment of parenteral
nutrition-associated cholestasis (PNAC):
Diagnostic criteria for PNAC [52]:
 Continuous parenteral nutrition ≥14 days
 Serum DB >34umol/L (2 mg/d1)
 Clinical manifestations of yellowish discoloration of
skin, hepatosplenomegaly, elevated transaminase
levels and (or) lighter stool color
 Exclusion of other diseases causing cholestasis
(various biliary malformations causing biliary
obstruction, hereditary metabolic diseases and
hepatitis caused by bacterial and viral infections)
Clinical treatment of PNAC:
 Protect the liver and gallbladder: ursodesoxycholic
acid 15 mg/(kg/d), three times daily, by mouth
 Do not lightly fast; increase enteral nutrition, reduce
the proportion of parenteral nutrition, and medium
and long-chain fat emulsion ≤1 g/(kg/d)
 Additionally supplement vitamin E 10 mg/(kg/d),
twice daily, by mouth
5. Diagnostic criteria for and clinical treatment of
congenital hypothyroidism [53].
Diagnostic criteria: 1 week after birth, draw blood
to test serum thyroid-stimulating hormone (TSH),
total triiodothyronine (TT3), total thyroxine (TT4),
free triiodothyronine (FT3) and free thyroxine (FT4).
If blood test shows no abnormality but there are clin-
ically suspicious symptoms of hypothyroidism, retest
the thyroid function. Suspicious symptoms of preterm
children’s hypothyroidism include persistent jaundice,
lethargy, less crying, low and weak crying, slow heart
rate, low and blunt heart sounds, poor digestion
(weak sucking, feeding intolerance), recurrent hypo-
glycemia, etc.
 If blood TSH is >10 mU/L and FT4 is decreased, the
child will be diagnosed with congenital
hypothyroidism.
 If blood TSH is >10 mU/L and FT4 is normal, the
child will be diagnosed with high TSH
hyperlipidemia.
 If blood TSH is normal or decreased and FT4 is
decreased, the child will be diagnosed with
secondary or central hypothyroidism.
Clinical treatment:
 In line with criterion (1), levothyroxine (Euthyrox)
from a starting therapeutic dose of 10–15ug/(kg/d),
daily, by mouth.
 In line with criterion (2), retest 1 week later. If TSH
is still >10 mU/L, give Euthyrox 4–8ug/kg/d, daily,
by mouth.
 In line with criterion (3), retest 1 week later. If FT4
is still decreased, give Euthyrox 4– 8ug/kg/d, daily,
by mouth.
 If TSH always maintains at 6–10 mU/L, without
treatment, regularly follow up thyroid function.
 If FT4 and TSH are normal, children with decreased
TT3 or TT4 are given no treatment.
 For children with abnormal test results, draw blood
for retest in 1–2 weeks. Adjust the therapeutic dose
based on the concentrations of blood TSH and FT4
and the children’s weight.
6. Diagnostic criteria for and clinical treatment of
hypocalcemia [54]
Diagnostic criteria:
Total serum calcium is less than 1.75 mmol/L (7.0 mg/dl)
or free calcium is less than 0.9mmom/L (3.5 mg/dl).
Clinical treatment:
 For children with clinical seizures or heart rhythm
disorders, which cannot be explained by other
diseases, give them slow intravenous injection of 10 %
calcium gluconate 2 ml/kg, and use 5 % glucose
injection after dilution by onefold. Then according to
the retest result, decide whether to continue
intravenous injection or switch to oral medication.
 For children with stable conditions, give them tube
feeding or oral 10 % calcium gluconate.
Stage II: follow-up period after discharge from the NICU
1. Develop a follow-up observation table for preterm
children <34 weeks, and require the children’s health
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Table 3 Modified Bell staging criteria for neonatal necrotising enterocolitis
Staging Systemic symptoms Gastrointestinal symptoms Radiological signs Treatment
IA Suspected NEC Temperature instability, apnoea,
bradycardia, lethargy
Gastric retention, mild abdominal distension,
fecal occult blood positive
Normal or intestinal dilation,
mild ileus
Absolute fasting, gastric decompression,
antibiotic therapy for 3 days, waiting for
pathogen culture results
IB Suspected NEC Same as IA Bright-red blood from rectum Same as IA Same as IA
IIA proven NEC (mildly ill) Same as IA Same as IA or IB, plus absent bowel sounds,
and (or) abdominal tenderness,
Intestinal dilation, ileus,
pneumatosis intestinalis
Same as IA, absolute fasting. If 24–48 h
culture shows no abnormality, use
antibiotics for 7– 10 days
IIB proven NEC (moderately ill) Same as IIA, plus mild metabolic
acidosis and mild thrombocytopenia
Same as IIA,plus absent bowel sounds, definite
abdominal tenderness, and (or) abdominal
cellulitis or right lower quadrant mass
Same as IIA, plus portal vein
gas, and (or) ascites
Same as IIA, absolute fasting. Supplement
blood volume, treat acidosis, and use
antibiotics for 14 days
IIIA Advanced NEC
(severely ill, bower intact)
Same as IIB, plus hypotension,
bradycardia, severe apnea, mixed
acidosis, DIC, neutropenia, anuria
Same as IIB, plus signs of generalized peritonitis,
abdominal distension or marked tenderness,
and redness and swelling of abdominal wall
Same as IIB, ascites Transfer to the Surgical Department
of Children’s Hospital for observation
IIIB Advanced NEC
(severely ill, bowel perforated)
Same as IIIA, plus suddenly
aggravation of conditions
Same as IIIA, plus sudden aggravation
of abdominal distension
Same as IIB, pneumoperitoneum Transfer to the Surgical Department
of Children’s Hospital for surgery









care medical staff to record the data of follow-up
every time in detail.
2. Require the preterm children to revisit the
hospital’s Child Health Clinic for referral 2 weeks,
4 weeks and 3 months after discharge, and follow
up once every 2–4 weeks according to the
preterm children’s conditions 4 weeks later.
3. Call the children’s parents 1–2 day before every
referral and require them to bring the children to
our hospital for referral on time, and ask them to
bring all medical data.
4. Contents of referral at the Child Health Clinic
include measurement of physical growth and
development, assessment of neuropsychological
development, nutritional assessment and feeding
guidance. According to different conditions of the
preterm children during hospital stay, choose
whether to conduct blood, liver function, thyroid
function, head B-mode ultrasound or cranial
magnetic resonance imaging (MRI), retinopathy
(ROP) screening, hearing screening and other tests.
5. Explain the current follow-up results in detail to the
parents, and appoint the time and contents of next
follow-up.
6. Call the parents again on the night or the next day
of follow-up every time to inquire about follow-up
conditions in detail, and again record all follow-up
results.
7. Follow-up period: at least 3 months.
Data collection and management
Including the collection of clinical data of preterm chil-
dren during the NICU stay and follow-up data after dis-
charge from the NICU.
Collection of clinical data during the NICU stay
1. Collection of general data of the objects of study:
(a)Sex, gestational age, birth weight, birth head
circumference, birth body length, mode of delivery,
5-minute Apgar score, etc., of preterm children
(b)Mother’s pregnancy complications and
comorbidities: premature rupture of membrane
>24 hours, placental abruption, chorioamnionitis,
pregnancy-induced hypertension syndrome,
preeclampsia, gestational diabetes, hyperthyroidism,
hypothyroidism, systemic lupus erythematosus,
kidney disease, cholestasis, acute liver failure,
syphilis infection, etc.
(c)Special treatment: nasal continuous positive airway
pressure (nCPAP), intubation and mechanical
ventilation (MV), use of pulmonary surfactant (PS),
thoracentesis, bone marrow biopsy, thoracic
drainage, peritoneal dialysis, etc.
2. Collection of case data during the NICU stay:
Incidence and outcome of feeding intolerance in preterm
children, neonatal necrotizing enterocolitis, cholestasis,
parenteral nutrition-associated cholestasis and congenital
hypothyroidism
3. Collection of enteral and parenteral nutrition and
defecation conditions during the NICU stay:
(a)Milk opening time (h), total amount of daily milk
(ml) and calories (kcal), total amount of daily
parenteral nutrition (ml) and calories (kcal), total
volume of daily fluids (ml) and total calories (kcal)
(b)The number of daily bowel movements, times of
daily enema, trait and color of stool every time,
meconium drainage time (h)
(c)Gastric residual volume (ml) and nature, times
and nature of vomiting, and abdominal distension
(d)Time to achieve full enteral nutrition (d), and
total time of parenteral nutrition
4. Collection of physical growth and development
indicators during the NICU stay:
(a)Weight: weight will be measured at admission,
once every day during hospital stay and before
discharge with a baby electronic scale, and the
data will be accurate to 10 g.
(b)Body length: body length will be measured at
admission, once every week during hospital stay
and before discharge, and the data will be
accurate to 0.1 cm.
(c)Head circumference: head circumference will be
measured at admission, once every week during
hospital stay and before discharge, and the data
will be accurate to 0.1 cm.
5. Collection of laboratory indicators during the NICU
stay:
(a)Daily monitoring of peripheral blood glucose and
transcutaneous bilirubin
(b)Weekly detection of blood, liver and kidney function
(total protein, albumin, total bilirubin, direct
bilirubin, alkaline phosphatase, bile acids, alanine
aminotransferase, aspartate aminotransferase,
γ-glutamyl transferase, urea nitrogen, creatinine)
and electrolytes (mainly calcium and phosphorus)
(c)Test of serum thyroid function 1–2 weeks after
admission, including TSH, TT3, TT4, FT3 and FT4
Collection of follow-up data after discharge from the NICU
1. Weight: weight will be measured once 2 weeks,
4 weeks and 3 months after discharge, respectively,
and the data will be accurate to 10 g.
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2. Body length: body length will be measured once
2 weeks, 4 weeks and 3 months after discharge,
respectively, and the data will be accurate to 0.1 cm.
3. Head circumference: head circumference will be
measured once 2 weeks, 4 weeks and 3 months after
discharge, respectively, and the data will be accurate
to 0.1 cm.
Sample size justification
We calculate the sample size based on the chi-square
test comparison of the food intolerance rate during
NICU between groups. Our previous pilot study shows
that the rate of food intolerance during NICU for con-
trol patients is about 85 %. We expect that the interven-
tion group will have a reduced intolerance rate to be
75 %. With these assumptions, we will need 148 infants
in each group to finish the NICU part of the study to
reach 80 % power and 5 % Type I error rate. Assuming
that the dropout rate to be 20 %, we will need to enroll
185 infants in each group.
Statistical analysis
Preliminary analysis
Patients’ characteristics will be summarized using mean ±
SD for continuous variables and frequency (percentage)
for categorical variables by groups. Continuous variables
will be transformed if there is a normal assumption
violation.
Primary outcome
The rates of food intolerance during NICU will be sum-
marized and compared using the chi-square test. A p
value <0.05 indicates a significant difference in rates be-
tween the two groups. We will also fit the logistic re-
gression model with food intolerance status as the
outcome variable, and group as the main predictor adjust-
ing for covariates. In the case that the number of intoler-
ance events is large enough, we will consider using a
Poisson model to model the number of intolerances.
Secondary outcome
The time to reach enteral nutrition (parenteral nutri-
tion), length of hospital stay, meconium drainage time
during the NICU stay will be summarized and compared
using Kaplan-Meier estimators and logrank tests. Cox
models will also be fitted for time-to-event data adjust-
ing for baseline covariates. The number of times of self-
defecating per day will be compared using the Poisson
model adjusting for baseline covariates. The rates of co-
morbidity will be compared using Poisson models. The
plasma total protein, albumin level, calcium, alkaline
phosphatase levels before discharge from the NICU will
be compared using t tests. Growth rates measure by
weight, body length, and head circumference during the
NICU and within 3 months of discharge will be analyzed
using repeated measurement analysis of covariance
models. All analysis will be conducted using SAS 9.4
(SAS Institute, Cary, NC, USA).
Discussion
Extensively hydrolyzed milk protein formula can acceler-
ate gastric emptying and gastrointestinal transit time,
and promote gastrointestinal hormone secretion, and
these mechanisms are conducive for the gastrointestinal
tolerability of preterm children, thereby lowering the in-
cidence of gastroesophageal reflux and feeding intoler-
ance in preterm children, achieving full enteral nutrition
as soon as possible and reducing the time of parenteral
nutrition. In China, more and more medical organiza-
tions have started using extensively hydrolyzed milk pro-
tein formula to feed preterm children, but so far there is
no clear conclusion on whether low-energy low-protein
extensively hydrolyzed formula can meet the high nutri-
tional needs of preterm children in the feeding period,
and there is a lack of relevant studies and conclusions
on whether feeding with extensively hydrolyzed milk
protein formula in the early stage of life will affect the
subsequent growth and development of preterm chil-
dren. As the conflict between the high nutritional needs
and low gastrointestinal tolerability of preterm children
with a gestational age of less than 34 weeks is an un-
avoidable issue, we have designed this study protocol,
aiming to increase a new and truly safe and effective en-
teral nutritional prescription. Our study observes the ef-
fect of extensively hydrolyzed milk formula on the
feeding intolerance, enteral and parenteral nutrition,
spontaneous fecal discharge and other complications in
preterm children with a gestational age of less than
34 weeks during the NICU stay; it also is the first con-
trolled clinical study with long-term observation of the
growth and development of preterm children fed with
such formula in the early stage of life. Our study time in-
cludes NICU stay and 3-month follow-up after discharge
of preterm children. The results of this study will con-
firm that feeding preterm children with such formula
during the NICU stay is safe and effective, and does not
affect the normal growth and development of preterm
children in the early stage of their lives.
Trial status
We started the enrollment in November 2014 and the
trial is expected to end in November 2017.
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